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ABSTRACT
Recent assassinations and terrorist attacks demonstrate the need for a more effective
antidote against nerve agents and other organophosphate (OP) compounds which inhibit the
nervous system enzyme acetylcholinesterase (AChE). This study explored the changes in gene
expression induced by novel phenoxyalkyl pyridinium oximes (U.S. patent 9,277,937) that have
demonstrated the ability to cross the blood-brain barrier and attenuate brain damage in a rat model.
More specifically, this study determined whether rats treated with high levels of a surrogate for
the nerve agent sarin (nitrophenyl isopropyl methylphosphonate; NIMP) and rats treated with
NIMP followed by a novel oxime displayed significant differences in their levels of messenger
RNA.
First, RNA samples were drawn from brain regions susceptible to damage by seizureinducing OP exposure levels (piriform cortex and hippocampus), harvested from rats treated with
NIMP alone or NIMP followed by a novel oxime. The samples of rat brain RNA were converted
to complementary DNA (cDNA) via reverse transcription. The resultant cDNA was used in
quantitative polymerase chain reaction (qPCR) to examine expression levels of genes that reflect
inflammation (Ccl2) and nerve growth and repair (Ngfr) in the piriform cortex, along with
expression levels of genes involved in potential brain damage repair (Bdnf) and astrocyte damage
(Gfap) in the hippocampus. Following these initial four genes, two additional immediate early
genes were evaluated, also in the hippocampus: Fos, associated with signal transduction, and
Bcl2l1, which may provide neuroprotection. Changes in the levels of gene expression were
quantified and compared across the experimental animal groups, i.e., NIMP alone, NIMP plus
novel oxime, novel oxime alone, and vehicle controls.
Bdnf, Fos, and Bcl2l1 showed statistically significant transcriptional changes between

3

several of the NIMP only and oxime combination groups, indicating that novel oximes may be
able to directly affect these genes’ expression and thereby attenuate NIMP-related neural damage.
While the other genes did not display statistical significance, average cycle threshold (Ct) values
for NIMP, oxime, combination, and vehicle groups still demonstrated notable differences
suggestive of oxime therapeutic efficacy. Ultimately, these comparisons should demonstrate
whether novel oximes can remediate some of the damage from OP poisoning and stimulate tissue
repair. The data produced also support the OP-induced neuropathological and behavioral changes,
as well as the therapeutic effects following novel oxime treatment, observed in live rats.

4

INTRODUCTION
The toxicity of organophosphates (OPs), including nerve agents and some insecticides,
stems from their inhibition of the enzyme acetylcholinesterase (AChE) in the central and peripheral
nervous systems. The neurotransmitter acetylcholine (ACh) is present at neuromuscular junctions
and throughout the central nervous system, making it instrumental in muscle contraction,
respiratory function, functions of the autonomic nervous system, and higher brain functions such
as cognition.
Normally, within milliseconds of release and subsequent binding to its receptors, ACh is
hydrolyzed by AChE into choline and acetic acid, allowing for normal cholinergic function. Any
delay in the degradation of ACh has an immediate effect as a result of the accumulation of ACh,
which causes prolonged transmission and excitation. Organophosphates are some of the most
potent AChE inhibitors, capable of persistent inhibition which can last days and may become
irreversible if a time-dependent dealkylation process known as “aging” occurs. Inhibition occurs
following binding of the OP to the AChE active site, as the result of phosphorylation of the serine
at the active site (Satoh and Gupta, 2010).
Following exposure to an OP, the subsequent buildup of ACh in neuromuscular junctions
and synapses leads to overstimulation of both muscarinic and nicotinic acetylcholine receptors.
Overstimulation of muscarinic receptors prompts acute signs including salivation, urination,
diarrhea, bradycardia, and broncho- and laryngospasm, while nicotinic effects include vomiting,
muscular fasciculation, and paralysis of the respiratory muscles (Satoh and Gupta, 2010). High
exposure may also prompt symptoms originating within the CNS, including generalized or partial
seizures, impaired coordination, and respiratory failure due to inhibition of the brain stem’s
respiratory center. OP-induced overstimulation of muscarinic ACh receptors within the brain has
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been connected to the onset of seizures, and overstimulation of nicotinic receptors may lead to the
propagation of excitatory postsynaptic potentials.
It has also been demonstrated that seizure-like activity prompts inflammatory responses in
the brain, impacting neuronal excitation and epileptic processes. Proinflammatory cytokines (such
as Ccl2) are produced during seizures, while activation of astrocytes and microglia contributes to
damage following convulsions. Seizures also damage the blood-brain barrier (BBB), causing
leakage which enables the entry of peripheral inflammatory molecules that prompt further injury
(Satoh and Gupta, 2010). As a result, prolonged seizures have been implicated as one of the main
contributors to permanent brain damage, manifest through behavioral alterations and cognitive
deficits lasting years after exposure. Two particular brain regions, the piriform cortex and
hippocampus, have been observed throughout the literature to experience tissue damage more
strongly and more frequently following seizure-inducing levels of the nerve agent sarin (Spradling
et al., 2011).
As evidenced by recent events, OP poisoning is a concern not only for members of the
military but for civilian populations either accidentally or purposefully exposed to nerve agents
and OP pesticides. The current treatment for OP poisoning involves atropine, which blocks
peripheral muscarinic ACh receptors, and pralidoxime (2-PAM), an oxime which reactivates the
inhibited AChE. The main deficiency of this therapy is 2-PAM’s inability to cross the BBB to
reactivate brain AChE as a result of the permanent positive charge contained within 2-PAM’s
pyridinium ring. Thus, while the current antidote can enable survival through the alleviation of
peripheral effects, 2-PAM is unable to prevent permanent brain damage. Novel substituted
phenoxyalkyl pyridinium oximes (U.S. patent 9,227,937) synthesized by this laboratory
incorporate increased lipophilicity, allowing them to more easily cross the BBB, and have provided
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convincing evidence of brain penetration and AChE reactivation in vivo using rats, although they
are typically less effective reactivators (Chambers et al., 2013).
Earlier in vivo survival experiments have shown that rats treated with a combination of a
novel oxime alone or in combination with 2-PAM usually displayed lower levels of mortality than
those treated with 2-PAM alone. Some of these novel oximes also showed a shorter time to
cessation of seizure-like behavior than 2-PAM, strongly suggesting entry of the oximes into the
brain (Chambers et al., 2016). Additionally, the lead novel oxime showed a suppression of glial
fibrillary acidic protein (Gfap) in histochemical studies that 2-PAM did not (Pringle et al., 2018)
and neuroprotection as indicated by NeuN nerve cell nuclear staining, while 2-PAM did not
(unpublished). These histological data also strongly suggest that some of our novel oximes can
enter the brain. Other studies conducted by this laboratory have also produced preliminary data on
altered gene expression in the piriform cortex. These observed changes, some of which indicated
inflammation and histological damage, followed the administration of high levels of NIMP in
laboratory rats. One of the lead novel oximes showed some ability to reduce these changes in gene
expression prompted by NIMP. Ultimately, the changes in gene expression discussed here will
help to further substantiate the novel oximes’ capacity for attenuating brain damage.
In place of actual nerve agents, this lab has developed non-volatile surrogates for use in
experimentation. While the surrogates differ by leaving group, they phosphorylate AChE with the
same chemical moiety as their respective nerve agents, making them highly relevant for both in
vitro and in vivo use (Meek et al., 2012). In this study, nitrophenyl isopropyl methylphosphonate
(NIMP), a sarin surrogate, was employed. Messenger RNA (mRNA) was used as an indicator of
gene expression because it codes for the production of new proteins and thus reflects the response
of the tissue to chemical challenge.
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Ultimately, the objective of this study was to evaluate any changes in gene expression
prompted by the novel oximes. It was hoped that these changes would indicate the oximes’
therapeutic properties, namely the ability of the novel oximes to up-regulate neuroprotective genes
and/or down-regulate inflammatory or damage-reflective genes. The results of this study,
therefore, serve to expand on previously observed changes induced by novel oximes and establish
their potential in attenuating OP neural damage via changes in gene expression.

Oxime 1
Oxime 20

n=4
n=4

R = 4-ClR = 4-Ph-CH2-O-

FIGURE 1: Generic structure of novel substituted phenoxyalkyl pyridinium oximes, where n is
the number of C’s in the alkyl chain and R is the substitution on the phenoxy moiety.

FIGURE 2: Structures of sarin and its surrogate, NIMP.
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METHODS
Before the start of this study, adult male (250-300g) Sprague Dawley-derived rats were
administered subcutaneously (SC) either a high sublethal dosage of the sarin surrogate NIMP
(0.325mg/kg) or vehicle (DMSO). At 1-hour post-NIMP exposure, peak inhibition (about 80%) of
brain AChE and signs of hypercholinergic toxicity, including seizure-like behavior, occur. At this
point, rats were administered intramuscularly (IM) 146 µmoles/kg of a novel oxime or 2-PAM in
Multisol (48.5% H2O, 40% propylene glycol, 10% ethanol, 1.5% benzyl alcohol) or the vehicle
alone (Multisol). This oxime dosage is equivalent to the human use of three auto-injectors, the
method of delivery used by the military following an OP poisoning event. Three rats were collected
for each treatment, representative of either an oxime alone, NIMP alone, a combination of oxime
and NIMP, or the vehicles. Rats were euthanized 2 hours after oxime administration. The piriform
cortex and hippocampus were quickly dissected, placed in RNAse-free tubes, snap frozen in liquid
nitrogen, and stored at -80°C until used for total RNA extraction. Total RNA from both brain
regions was purified using the RNeasy® Plus Mini Kit from Qiagen (Valencia, CA), following the
manufacturer’s instructions.
At the start of the present work, the frozen RNA samples were removed from long-term
storage. The purity and quantity of the samples were determined by Abs 260/230 and 260/280
ratios using a Nanodrop ND-1000 spectrophotometer, in order to ensure that the RNA had not
degraded, with a concentration of no less than 40 ng/µL. The RT2 First Strand Kit from Qiagen
was used to reverse transcribe 0.5µg of total RNA into cDNA following the manufacturer’s
instructions. Each RNA sample was treated with a genomic DNA elimination mix prior to reverse
transcription to eliminate any remaining genomic DNA. RE3 reverse transcriptase was primed in

9

an unbiased manner with random hexamers and oligo-dT primers. The plate was then spun in a
Marathon tabletop centrifuge at roughly 1900 RPM for one minute.
PCR, a method commonly used in assessing genes, determines relative values for gene
expression via fluorescence emissions. Once the mix’s DNA polymerase synthesizes a new DNA
strand, its exonuclease activity separates the fluorescent dye from a quencher dye. As PCR
continues, more and more of the dye is released, intensifying fluorescence. The level of
fluorescence, quantified by the PCR machine, is indicative of the amount of mRNA originally
present in the tissue. More intense fluorescence, or an earlier break of the machine’s cycle
threshold (Ct), indicates higher initial mRNA levels. In measuring fluorescence against a
threshold, the PCR machine takes into account the emission intensity of the reporter dyes (HEX
and FAM) to the reference dye ROX. A more highly expressed gene produces fluorescence in a
smaller number of cycles, reaching the threshold at an earlier cycle. Thus, more gene expression
is indicated by a smaller Ct value, or the number of cycles required to cross the threshold.
Duplex qPCR was performed on the Stratagene MX3005 qPCR system with IDT
PrimeTime® qPCR Assays. Assays contained 500 nm primers and 250 nm fluorogenic probes
designed by IDT for both the genes of interest and RPLP1. The mRNA values were normalized
using the housekeeping gene RPLP1 (ribosomal protein, large, P1), chosen because it had
previously displayed the smallest changes between sample groups in arrays containing the same
oximes and oxime combinations. RPLP1, notated by the marker dye HEX, was run in each well in
addition to the gene of interest in order to provide a “housekeeping” or baseline comparison, as
well as a positive control. Each duplex qPCR was performed in triplicate in a final reaction volume
of 20µl, using PrimeTime Gene Expression Master Mix, which included addition of the reference
dye ROX per the manufacturer’s instructions. The cDNA was assayed at concentrations
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empirically determined for each gene of interest, denoted by the marker dye FAM, and ranging
from 36 to 75 ng. The cycling protocol was as follows: 95° C for 3 min, followed by 40 cycles of
15 s at 95° C, and then 1 min at 60° C. In all experiments, three wells without template were
included as negative controls. Standard curves of both the housekeeping gene (RPLP1) and the
gene of interest were used to calculate the PCR efficiency using dilutions of a template mixture
from pure to 1:1000. Ct values for each well were calculated using the Stratagene MxPro qPCR
software by manually defining the non-adaptive baseline and threshold per the manufacturer’s
instructions. The Ct values of each gene of interest were normalized to the Ct values of RPLP1 to
correct for variations in pipetting. A total of 3 biological replicates and 9 technical replicates were
collected for each treatment.
After normalization, mean Ct differences from each treatment and the vehicle controls
were analyzed for outliers and normal distribution using the Kolmogorov-Smirnov test. After
outlier removal, some of the groups were normally distributed, but unequal variances barred the
use of an ANOVA. Instead, the non-parametric Kruskal-Wallis test was used to look for
statistically significant differences among the groups at P < 0.05. When difference was found, the
Mann-Whitney U test was used to determine which of the groups were statistically different at P
< 0.05. The statistically different groups were then corrected for multiple comparisons using the
Benjamini-Hochberg method (Benjamini and Hochberg, 1995).
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RESULTS
As defined in this study, a statistically significant change is one which produces a P value of P
< 0.05, indicating a 90% confidence interval. Considering all six genes of interest, the following
P values were determined:
●
●
●
●
●
●

Ccl2: no significant changes (P = 0.26)
Ngfr: no significant changes (P = 0.16)
Gfap: no significant changes (P = 0.99)
Bdnf: significant changes (P = 0.000021)
Fos: significant changes (P = 0.045)
Bcl2l1: significant changes (P = 1.0 x 10-15)

Bdnf
Of the initial four genes studied, Bdnf was the only gene to display statistically significant
changes (P = 0.000021) among experimental groups. NIMP alone and Oxime 1 alone both
repressed Bdnf expression to similar levels, displaying the greatest down-regulation of Bdnf and
prompting no statistically significant differences compared to the control. However, when
compared to that observed for the NIMP only group, Bdnf expression was significantly increased
by 2-PAM and Oxime 20 alone as well as by the combination groups of NIMP plus 2-PAM and
NIMP plus Oxime 1. These four groups also displayed statistically significant differences when
compared to the vehicle control group, increasing expression of Bdnf. Oxime 20 alone and 2-PAM
alone increased Bdnf expression to similar levels, with both groups displaying statistical
significance when compared to Oxime 1 alone.
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FIGURE 3: The vertical axis denotes changes in hippocampal Bdnf average Ct relative to the
vehicle control value, which was set equal to zero. A value above the line reflects an increase in
expression, and a value below the line reflects a decrease in expression. The * symbol indicates a
statistically significant difference from NIMP, and the ∆ symbol indicates a statistically significant
difference from the vehicle group. The ▼ symbol indicates a statistically significant difference
from Oxime 1. Statistical significance determined at P < 0.05.
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Fos
The Ct values for Fos displayed statistical significance, with P = 0.045 across all
experimental groups. The highest level of Fos expression was observed for the NIMP only group.
Significant differences were observed between the 2-PAM and Oxime 20 only groups, with the 2PAM expression levels approximating those of the vehicle control group. Oxime 20, conversely,
significantly up-regulated Fos. Significant differences were also seen between the vehicle and
NIMP plus 2-PAM groups, with the 2-PAM combination group down-regulating Fos to the
greatest degree, lowering expression beyond even that of the control group.
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FIGURE 4: The vertical axis denotes changes in hippocampal Fos average Ct relative to the
vehicle control value, which was set equal to zero. A value above the line reflects an increase in
expression, and a value below the line reflects a decrease in expression. The ∆ symbol indicates a
statistically significant difference from the vehicle group. The ▼ symbol indicates a statistically
significant difference between 2-PAM and Oxime 20. Statistical significance determined at P <
0.05.
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Bcl2l1
The Ct values for Bcl2l1 displayed marked statistical significance, with P = 1.0 x 10-15
across all experimental groups. The NIMP only group down-regulated Bcl2l1, prompting
expression levels below those observed for the vehicle control group. Significant differences were
observed between the NIMP only group and the vehicle, 2-PAM alone, and both combination
groups. While either oxime alone was unable to increase Bcl2l1 expression, both the NIMP plus
2-PAM and NIMP plus Oxime 20 combination groups prompted expression of Bcl2l1 at levels
which approximated those seen for the vehicle control group.
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FIGURE 5: The vertical axis denotes changes in hippocampal Bcl2l1 average Ct relative to the
vehicle control value, which was set equal to zero. A value above the line reflects an increase in
expression, and a value below the line reflects a decrease in expression. The * symbol indicates a
statistically significant difference from NIMP, and the ∆ symbol indicates a statistically significant
difference from the vehicle group. Statistical significance determined at P < 0.05.
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DISCUSSION
Ccl2 (C-C motif chemokine ligand 2; piriform cortex)
The gene Ccl2, a proinflammatory cytokine, has been associated in the literature with
inflammation and immune function (Liu et al., 2017). Since inflammation is one of the factors
implicated in long-term brain damage, the novel oximes were expected to suppress the
inflammatory response prompted by OP exposure. In previous work by this lab, Ccl2 demonstrated
a strong response with inflammatory PCR arrays (Dail, personal comm., 2018). Thus, in this study,
Ccl2 acted as a positive control, and was the first gene to be run using RNA from the piriform
cortex (PC).
Both PC genes were only assayed with Oxime 1, leaving four experimental groups: NIMP;
Oxime 1; NIMP plus Oxime 1; and vehicle control. While the results were not statistically
significant, multiple trends may still be observed. As expected, the lowest level of Ccl2 expression
was demonstrated by the vehicle group. NIMP prompted the highest level of expression, indicating
that NIMP plays a role in activating Ccl2 and causing the resultant inflammation.
Oxime 1, when administered alone, trended toward a marked repression of Ccl2
expression, indicating its ability to attenuate OP-induced inflammation. The combination of NIMP
plus Oxime 1 elicited higher gene expression than that of Oxime 1 alone, but lower expression
than that of the NIMP only group. These results suggest that Oxime 1 is able to decrease
transcription of Ccl2. As Ccl2 is a proinflammatory gene, Oxime 1 is thus acting therapeutically,
demonstrating its potential to attenuate the factors involved in permanent brain damage.
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Ngfr (nerve growth factor receptor; piriform cortex)
In the literature, the neurotrophin nerve growth factor (Ngf) is acknowledged as essential
in the postnatal development of basal and striatal cholinergic neurons that project into the
hippocampus and regulate cognitive functions such as learning and memory. Previous experiments
have shown that exposure to the OP chlorpyrifos stimulates significant decreases in Ngf mRNA
levels, indicating OP-induced damage as a precursor for inhibited neural development (Betancourt
et al., 2006).
As a potential limiting factor, it should be noted that Ngfr was one of multiple genes
isolated from the original Ngf gene. Thus, it is possible that the chosen gene for this study, Ngfr,
may not have been the best representative of Ngf functionality in relation to NIMP and oxime
treatments.
Like Ccl2, Ngfr was only assayed with Oxime 1, leaving four experimental groups. While
no significance was found, multiple trends were still established. Oxime 1 alone prompted the
highest level of Ngfr expression, surpassing control levels. However, the combination of NIMP
plus Oxime 1 displayed the lowest level of Ngfr expression, even falling below that observed for
the NIMP group. Thus, it is possible that Oxime 1, in combination with NIMP, actually works to
suppress Ngfr expression levels, suggesting that Oxime 1 is unable to attenuate NIMP damage by
up-regulating Ngfr.

Gfap (glial fibrillary acidic protein; hippocampus)
In the literature, Gfap expression increases are associated with neural damage and
neurodegeneration, as Gfap is up-regulated following neural injury and resultant cellular signaling
in astrocytes (Benkovic et al., 2006). Gene expression levels of Gfap were also observed to
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increase following chlorpyrifos exposure in rats, suggesting heightened astrocyte activity as a
response to OP poisoning (Betancourt et al., 2006). Previous experiments performed by this
laboratory have also demonstrated that, following challenge with an OP, administration of either
no oxime therapy or 2-PAM resulted in increased Gfap expression in the piriform cortex and
hippocampus. However, administration of novel Oxime 20 resulted in Gfap expression levels
which were statistically indistinguishable from control levels, providing support for the oximes’
ability to enter the brain and promote normalization (Pringle et al., 2018).
In support of these findings, this project found that the NIMP group prompted Gfap
expression higher than that observed for the vehicle control group, indicating that Gfap is activated
by OP exposure. While no significance was found, some of the novel oxime groups still elicited
demonstrable effects on Gfap expression. In suggesting their efficacy, two of the oximes given
alone, 2-PAM and Oxime 1, were able to reduce Gfap expression levels, and the combination of
NIMP plus Oxime 1 lowered Gfap expression below control levels. Thus, at least one novel oxime,
Oxime 1, supports the desired trend toward suppression of Gfap levels. Following from previous
findings, the results of this study suggest that Oxime 1, both alone and after NIMP exposure, may
therefore have therapeutic attributes in its ability to down-regulate Gfap and thus prevent neural
damage.

Bdnf (brain-derived neurotrophic factor; hippocampus)
In the literature, Bdnf has been associated with neural growth and repair. Bdnf mRNA
levels have been reported to increase following chlorpyrifos and methyl parathion exposure in the
cerebral cortex and hippocampus of juvenile rats, indicating that the proteins encoded by Bdnf
possess some relation to neuroprotection (Betancourt et al., 2007). Bdnf transcriptional increases
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have also been shown to prompt neuronal growth and repair following subarachnoid hemorrhage
(Lee et al., 2016).
As a neuroprotective gene, Bdnf was predicted to display increased activation and
associated protein production following the administration of novel oximes. In this study, as
expected, expression of Bdnf was significantly increased for several of the oxime and combination
groups, indicating that some novel oximes may be able to increase Bdnf transcription levels for
neuroprotective purposes. As novel oximes have previously been shown to reduce observed
seizure duration, it is possible they may achieve this attenuation through the reduction of NIMP’s
neurotoxic effects, primarily through their activation of Bdnf.
Within this study, it was observed that both 2-PAM and Oxime 20 alone were able to
significantly up-regulate Bdnf when compared to the NIMP only group. The finding that Oxime 1
alone repressed Bdnf to approximately the same level as NIMP was countered by the observation
that, when in combination with NIMP, Oxime 1 was able to significantly up-regulate Bdnf
expression. These findings suggest that the oximes were able to provide some degree of
neuroprotection, as Bdnf transcriptional increases correspond to neuronal growth and repair.
Likewise, the other two combination groups (with 2-PAM and Oxime 20) managed to increase
Bdnf transcription when compared to the NIMP only group, with the 2-PAM combination also
demonstrating significance. While the Oxime 20 combination did not differ significantly from the
NIMP group, its average Ct value closely approximated that of the vehicle control group,
indicating that Oxime 20 may be able to normalize Bdnf transcription, returning gene expression
levels to those observed in homeostasis.
These results demonstrate that 2-PAM and at least one of the novel oximes, Oxime 1, were
able to up-regulate Bdnf following NIMP exposure to levels which differed significantly not only
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from the NIMP group but from the baseline controls. Administered following NIMP exposure,
Oxime 20 may also possess some normalization capacity regarding Bdnf expression. Thus, all
three oximes were able to positively affect Bdnf expression, thereby demonstrating therapeutic
capacity following NIMP exposure.

Fos (Fos proto-oncogene; hippocampus)
In the literature, mRNA levels for Fos, a marker of neuronal activation, have been reported
to increase following chlorpyrifos and methyl parathion exposure in the cerebral cortex and
hippocampus of juvenile rats, indicating that Fos may play a role in indicating neural damage
(Betancourt et al., 2007). Fos was also identified as an immediate early gene which encodes a
nuclear protein involved in signal transduction, allowing it to play a role in long-term neuronal
plasticity resulting from changes to the cellular or extracellular environment (Perez-Cadahia et al.,
2011). Novel environmental stimuli have also been reported to increase Fos expression levels
within the hippocampus, indicating its role in neuronal excitation and changes related to
neuroplasticity (VanElzakker et al., 2008). Therefore, within this study, Fos was viewed as an
indicator of OP-induced neurological damage.
The NIMP only group displayed the highest levels of Fos transcription, markedly increased
over the vehicle control group, suggesting that Fos may play a role in indicating neural damage
following OP exposure. Thus, down-regulation of Fos could be related to normalization processes
following the administration of novel oximes.
Concerning the oxime only groups, Fos was significantly down-regulated by 2-PAM when
compared to Oxime 20, indicating that 2-PAM may be able to outperform Oxime 20 in reversing
any harmful effects of NIMP.
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The NIMP plus Oxime 20 combination returned Fos levels to those observed for the control
group, with no significant difference found between the two groups. This result suggests that
Oxime 20 may be able to induce control levels of Fos expression following NIMP exposure and
thus prompt a return to normalization, or homeostasis, following OP poisoning. In this regard, the
Oxime 20 combination was observed to more closely approximate the control group than that of
NIMP plus 2-PAM, which differed significantly from the vehicle group in lowering levels of Fos
transcription.
Following from these results, it can be concluded that both 2-PAM and Oxime 20 may be
able to play a role in neuroprotection through their normalization of factors related to NIMPinduced damage. These neurotoxic factors most likely prompt Fos expression as a type of alarm
system; thus, it is suggested that, through their down-regulation of Fos, the oximes are working to
reverse neural damage. This ability to dampen gene expression changes following NIMP exposure
could prove key in Oxime 20’s therapeutic potential, allowing it to attenuate OP-induced brain
damage and reduce the possibility of permanent neural deficits.

Bcl2l1 (Bcl2-like 1; hippocampus)
In previous studies, Bcl2l1 has been implicated as an immediate early gene pivotal to the
inhibition of neuronal apoptosis, and potentially able to provide neuroprotection against ischemic
brain injury. More specifically, the Bcl gene family was found to regulate neuronal development
and provide neuronal protection against neurodegenerative factors (Park et al., 2015). Upregulation of Bcl2l1 would therefore be associated with an increased potential for neuroprotection
and should have been observed with oxime administration following NIMP exposure.
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As observed within this study, the NIMP only group displayed statistically significant
differences when compared to the vehicle control group, 2-PAM alone, and both oxime
combination groups. Statistical significance in relation to the NIMP group was not found with
Oxime 20 alone, whose average Ct value roughly approximated that of NIMP alone.
Thus, while the oximes administered alone were observed to down-regulate Bcl2l1, both
of the combination groups, including that with Oxime 20, elicited similar expression of Bcl2l1.
Gene expression values for the combination groups most closely approximated the values observed
for the vehicle control group, with no significant differences found between the vehicle and the
Oxime 20 combination. As both combination groups up-regulated Bcl2l1 when compared to
NIMP, producing values which neared those of the vehicle control group, it is suggested that novel
oximes may exhibit some potential for normalization of Bcl2l1 expression. Thus, the therapeutic
potential of Oxime 20 may be related to its ability to increase Bcl2l1 expression to control levels,
allowing it to inhibit OP-induced apoptosis and provide neuroprotection following a poisoning
event.

One of the main limitations of this study concerns the three-hour post-exposure window
preceding sacrifice. Following NIMP exposure, a waiting period of one hour was undergone in
order to achieve peak brain AChE inhibition as well as clear physical signs of hypercholinergic
toxicity. Oximes were then administered, and the rats were euthanized two hours later. However,
as different genes may be affected independently of peak AChE inhibition, this three-hour window
may be too short of a timeframe to observe extensive changes in gene expression. As a result, these
findings reflect gene expression at a given time point, which may or may not represent the oximes’
peak response. Due to the different solubilities and rates of distribution and absorption of the tested
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oximes, it is also possible that the peak effects of individual oximes might occur at different time
points. Longer exposure windows, especially following administration of the oximes, could reveal
more nuanced or significant changes to gene expression, as the phenomenon is influenced by a
number of different factors unable to be fully accounted for here.
Other considerations include the OP used in this study. As NIMP is a nerve agent surrogate
compound which is not being studied by many research groups, no other laboratories at this time
have published work detailing its effects. It is important to note that NIMP may affect the chosen
genes of interest differently than its respective nerve agent, sarin. NIMP also functions differently
from other OP compounds that were not evaluated within this study, making these results NIMPspecific.
In addition, all six of the genes of interest were chosen based on previous literature,
occasionally in relation to different OP compounds. It is possible that some of these genes were
simply unresponsive to provocation with NIMP, or did not experience changes in their expression
within the experimental timeframe used here. The last two genes, Fos and Bcl2l1, were chosen in
light of this concern because of their identification as immediate early genes. It was expected that
gene expression changes would occur more quickly, and thus allow for observation within the
given window.
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CONCLUSION
This study aimed to elucidate and quantify the changes in gene expression prompted by the
administration of novel oximes. While not all genes of interest demonstrated statistically
significant differences, a number of the observed Ct values indicated the potential for
normalization of gene expression by the oximes in response to NIMP intoxication, or indicated
trends in the direction of significance. In the case of two damage-related genes, Ccl2 and Gfap,
novel oxime combinations were shown to decrease expression when compared to the NIMP only
group. These results demonstrated the novel oximes’ potential for attenuation of inflammation and
neural damage following OP exposure.
Novel oximes were also found to increase expression of the neuroprotective gene Bdnf,
suggesting neuroprotection via brain cell growth and repair. The novel Oxime 1 combination was
found to increase Bdnf expression above even control levels, indicating the potential for
attenuation, while the Oxime 20 combination approximated the vehicle control. The immediate
early genes Fos and Bcl2l1 also demonstrated changes in gene expression consistent with
normalization of gene transcription following OP exposure. For both genes, no significant
differences were found between the Oxime 20 combination and the vehicle control, indicating that
Oxime 20 may be able to induce a return to homeostatic gene expression levels following an OP
poisoning event.
This study thus supports the potential of the novel oximes to attenuate neural damage after
sublethal OP exposure, providing therapy via changes in gene expression. Their ability to upregulate neuroprotective genes and down-regulate damage-reflective genes, therefore normalizing
them to control levels, again suggests the novel oximes’ capacity to enter the brain and provide
neuroprotection not offered by the currently approved therapeutic. Ultimately, this study further
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demonstrates the novel oximes’ value in modern therapy, cementing them as promising
alternatives to the current antidote and highlighting their potential in the endeavor to save not only
lives, but brains.
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